[go: up one dir, main page]

WO2014174254A3 - Combination therapy of pulmonary arterial hypertension - Google Patents

Combination therapy of pulmonary arterial hypertension Download PDF

Info

Publication number
WO2014174254A3
WO2014174254A3 PCT/GB2014/051205 GB2014051205W WO2014174254A3 WO 2014174254 A3 WO2014174254 A3 WO 2014174254A3 GB 2014051205 W GB2014051205 W GB 2014051205W WO 2014174254 A3 WO2014174254 A3 WO 2014174254A3
Authority
WO
WIPO (PCT)
Prior art keywords
combination therapy
arterial hypertension
pulmonary arterial
opg
agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2014/051205
Other languages
French (fr)
Other versions
WO2014174254A2 (en
Inventor
Allan LAWRIE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PH Therapeutics Ltd
Original Assignee
PH Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PH Therapeutics Ltd filed Critical PH Therapeutics Ltd
Publication of WO2014174254A2 publication Critical patent/WO2014174254A2/en
Publication of WO2014174254A3 publication Critical patent/WO2014174254A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The disclosure relates to an agent or agents that inhibit the activity of both, Tumour Necrosis Factor Apoptosis-Inducing Ligand [TRAIL] and osteoprotegerin (OPG) and their use in the treatment of pulmonary hypertension and including agents that bind OPG ligands/receptors
PCT/GB2014/051205 2013-04-23 2014-04-17 Combination therapy Ceased WO2014174254A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1307269.9A GB201307269D0 (en) 2013-04-23 2013-04-23 Combination Therapy
GB1307269.9 2013-04-23

Publications (2)

Publication Number Publication Date
WO2014174254A2 WO2014174254A2 (en) 2014-10-30
WO2014174254A3 true WO2014174254A3 (en) 2014-12-24

Family

ID=48537633

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2014/051205 Ceased WO2014174254A2 (en) 2013-04-23 2014-04-17 Combination therapy

Country Status (2)

Country Link
GB (1) GB201307269D0 (en)
WO (1) WO2014174254A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11680101B2 (en) 2017-01-27 2023-06-20 Kymab Limited Anti-OPG antibodies
TW202021618A (en) 2018-08-17 2020-06-16 美商２３與我有限公司 Anti-il1rap antibodies and methods of use thereof
CN114624444B (en) * 2020-12-10 2024-11-26 中国医学科学院基础医学研究所 The role of immunoglobulin IgE in pulmonary hypertension

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998030693A2 (en) * 1997-01-14 1998-07-16 Human Genome Sciences, Inc. Tumor necrosis factor receptor 5
WO2013061048A1 (en) * 2011-10-25 2013-05-02 University Of Sheffield Pulmonary hypertension
WO2013064810A1 (en) * 2011-11-01 2013-05-10 University Of Sheffield Pulmonary hypertension

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998030693A2 (en) * 1997-01-14 1998-07-16 Human Genome Sciences, Inc. Tumor necrosis factor receptor 5
WO2013061048A1 (en) * 2011-10-25 2013-05-02 University Of Sheffield Pulmonary hypertension
WO2013064810A1 (en) * 2011-11-01 2013-05-10 University Of Sheffield Pulmonary hypertension

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
A LAWRIE ET AL: "Osteoprotegerin Blockade Prevents And Reverses Experimental Pulmonary Arterial Hypertension", AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1 May 2012 (2012-05-01), pages D97, XP055048904, Retrieved from the Internet <URL:http://ajrccm.atsjournals.org/cgi/reprint/185/1_MeetingAbstracts/A6515> [retrieved on 20130108] *
ALLAN LAWRIE ET AL: "Evidence of a Role for Osteoprotegerin in the Pathogenesis of Pulmonary Arterial Hypertension", THE AMERICAN JOURNAL OF PATHOLOGY, vol. 172, no. 1, 1 January 2008 (2008-01-01), pages 256 - 264, XP055048790, ISSN: 0002-9440, DOI: 10.2353/ajpath.2008.070395 *
HAMEED A G ET AL: "S151 TRAIL deficiency is protective in experimental pulmonary arterial hypertension", INTERNET CITATION, vol. 65, 1 January 2010 (2010-01-01), pages A68, XP002690361, Retrieved from the Internet <URL:http://thorax.bmj.com/content/65/Suppl_4/A68.2.abstract> [retrieved on 20130109] *
HAMEED ABDUL G ET AL: "Inhibition of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) reverses experimental pulmonary hypertension", JOURNAL OF EXPERIMENTAL MEDICINE,, vol. 209, no. 11, 22 October 2012 (2012-10-22), pages 1919 - 1935, XP008159134, ISSN: 1540-9538, DOI: L0.1084/JEM.20112716 *
KENGO F KUSANO: "Treatment for pulmonary hypertension including lung transplantation", GENERAL THORACIC AND CARDIOVASCULAR SURGERY, SPRINGER JAPAN, JAPAN, vol. 59, no. 8, 18 August 2011 (2011-08-18), pages 538 - 546, XP019941131, ISSN: 1863-6713, DOI: 10.1007/S11748-010-0747-Z *
SANDRA ET AL: "Osteoprotegerin (OPG) binds with Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL): Suppression of TRAIL-induced apoptosis in ameloblastomas", ORAL ONCOLOGY, ELSEVIER SCIENCE, OXFORD, GB, vol. 42, no. 4, 1 April 2006 (2006-04-01), pages 415 - 420, XP005345461, ISSN: 1368-8375, DOI: 10.1016/J.ORALONCOLOGY.2005.09.009 *
WATT VICTORIA ET AL: "OPG:TRAIL Ratio as a Potential Biomarker for Pulmonary Arterial Hypertension", CIRCULATION, vol. 120, no. 18, Suppl. 2, November 2009 (2009-11-01), & 82ND SCIENTIFIC SESSION OF THE AMERICAN-HEART-ASSOCIATION; ORLANDO, FL, USA; NOVEMBER 14 -18, 2009, pages S806, XP009179262, ISSN: 0009-7322 *

Also Published As

Publication number Publication date
WO2014174254A2 (en) 2014-10-30
GB201307269D0 (en) 2013-05-29

Similar Documents

Publication Publication Date Title
MX2015013170A (en) Dual specific binding proteins directed against tnfî±.
WO2014089169A3 (en) Immunotherapy with binding agents
MX2014013568A (en) Antibodies capable of binding to the coagulation factor xi and/or its activated form factor xia and uses thereof.
EP3088353B8 (en) Bilirubin particles and their preparation for use in therapy
WO2012062925A3 (en) Compounds and methods for treating pain
MX2014008102A (en) Dual variable domain immunoglobulins against receptors.
MX375221B (en) Compositions comprising anti-ceacam1 and anti-pd antibodies for cancer therapy
PH12014501164A1 (en) Anti-cd98 antibodies and methods of use thereof
EP3191131A4 (en) Tumor necrosis factor superfamily and tnf-like ligand muteins and methods of preparing and using the same
MX2021014242A (en) USE OF LINAGLIPTIN IN CARDIO- AND RENOPROTECTIVE ANTI-DIABETIC THERAPY.
EA201390506A1 (en) POLYPEPTIDES THAT BIND THE COMPONENT C5 OF THE HUMAN COMPLEX
NZ628433A (en) Chitosan-derived compositions
SI2900279T1 (en) GRPR antagonists for the detection, diagnosis and treatment of GRPR-positive cancer
IL237125A0 (en) Niclosamide and its derivatives for use in the treatment of solid tumors
ZA201406989B (en) Porous carbon particles for use in the treatment or prevention of liver disease
EP3052189A4 (en) Modulation of leukocyte activity in treatment of neuroinflammatory degenerative disease
WO2014159669A3 (en) Aptamers that bind to il-6 and their use in treating or diagnosing il-6 mediated conditions
ZA201402745B (en) Blood coagulation factor vii and viia derivatives, conjugates and complexes comprising the same, and the use thereof.
WO2012094328A3 (en) Hedgehog antagonists having zinc binding moieties
EA201301269A1 (en) METHOD OF TREATMENT OF PROGRESSIVE SOLID TUMORS
PT3041475T (en) Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them and methods of their use
MX2014010940A (en) The use of antithrombin in the treatment of pre-eclampsia.
EA201500363A1 (en) HUMAN ANTI-VEGFR-2 / KDR-ANTIBODIES
MX2015010023A (en) Anti-cd83 antibodies and use thereof.
WO2014174254A3 (en) Combination therapy of pulmonary arterial hypertension

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14719816

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 14719816

Country of ref document: EP

Kind code of ref document: A2